Under 10% of people eligible to benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it releases its initial guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be treated with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant barriers to broad access to the jabs that can assist patients in reducing significant weight, explains the organization.
Skinny Jab Shortage
Even in the present best projected scenario, the production of GLP-1 therapies might only reach about 100 million people – under 10% of eligible patients, according to the health organization.
The advice encourages governments and firms to increase access, through strategies such as voluntary licensing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple nations in 2026.
How Weight-Loss Jabs Function
The injections replicate a natural hormone to slow digestion, suppress the appetite and enhance satiety so individuals reduce food intake.
People typically begin shedding pounds within a few weeks of commencing the regular doses.
Research suggests users may see weight return within a year of discontinuing the treatment, because their normal hunger resume.
Being overweight or obese raises your chance for developing diseases, like diabetes, heart disease, brain attack, and specific cancers.
Obesity affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
